Pushing the boundaries of
innovation in oncology.
innovation in oncology.
Pushing the boundaries of
innovation in oncology.
innovation in oncology.
About
There is more innovation in cancer research today than ever before. Many of these efforts are disjointed and silo-ed and as a result often do not reach their full potential. If we can capture that potential, we believe it could greatly benefit cancer patients.
Cullinan uniquely applies open innovation to the development of scientific oncology assets. Our approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, we seek to develop assets that have the potential to dramatically improve the lives of those living with cancer.
Drug development through
the prism of modern-day
portfolio management.
the prism of modern-day
portfolio management.
Our Approach
Cullinan Oncology, Inc. is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
Team
At the core of any great company is its people. The Cullinan team is a group of accomplished professionals that share a vision for eradicating cancer.
Board of Directors
Anthony Davis has more than 25 years of professional experience working in GxP environments building quality assurance systems from initial conception to beyond commercial deployment. Anthony brings extensive experience within Quality Assurance and Compliance Systems from working with market leaders in the Life Sciences sector. Prior to joining Cullinan, Anthony led the development activities for all of Quality at Dicerna Pharmaceuticals, a leader in using ribonucleic acid interference (RNAi) to develop medicines, where he was responsible for all GXP activities. Before Dicerna, Anthony worked at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, Biogen, MassBiologics and Amgen.
Most recently, Irina was Senior Director, Head of Biomarkers at Agenus where she led translational biomarker development for a broad immune-oncology pipeline comprised of checkpoint antibodies, cell therapies and cancer vaccines. Prior to that, Irina led clinical biomarker strategy for BAVENCIO® (avelumab, aPD-L1 antibody) at EMD Serono. Previously, Irina was a translational research lead for small molecule inhibitors from discovery to Phase 2 development at Verastem.
John was most recently Executive Director for Monoclonal Antibody Clinical Development at Incyte.
Most recently, Natasha was Director of Analytical Sciences at Corvidia (acquired by Novo Nordisk) where she was responsible for CMC analytical control strategies of late preclinical and clinical biologics and combination products. Previous to that, Natasha held multiple positions of increasing responsibilities at ImmunoGen where she was responsible for supplier relationship management, product quality management and analytical control strategies of small molecules, monoclonal antibodies and antibody-drug conjugates from FIH (phase 1) thru BLA (phase 3).
Juliet is a corporate finance specialist, drawing from experience in varied finance roles across multiple industries. Juliet joins Cullinan from BlueRock Therapeutics, an engineered cell & gene therapy company, where she helped build out the finance function and support the organization through a significant growth period. Prior to BlueRock, she held positions in financial planning & analysis at Squarespace and HBO. Juliet received her B.S. from Lehigh University and her Master’s in Accountancy from Yeshiva University.
Nancy joined the Cullinan Oncology team with ten years of administrative experience. Prior to joining Cullinan Oncology, Nancy was an Executive Assistant at TESARO Inc. and Cubist Pharmaceuticals. Nancy earned a B.A. in Geography from Framingham State University.
Kristan brings 20 years of drug discovery and development experience. Her background spans small molecule, biotherapeutics, as well as antibody drug conjugate drug discovery and developent. She has served as a drug development consultant for the last 5 years to numerous biotech companies. Kristan previously held roles of increasing responsibility at Tarveda (Blend) Therapeutics, AVEO Pharmaceuticals, and Millennium Pharmaceuticals, after completing her post-doctoral training at Eli Lilly and Co. Kristan has successfully completed many IND submissions, with programs at all stages of clinical development. Kristan received a BS in Biochemistry from Susquehanna University and received her PhD in Cancer Biology from Wayne State University.
Nate has over 11 years of financial accounting and reporting experience. Prior to joining Cullinan, Nate was a Managing Director at CFGI where he advised clients across various industries, including life sciences and technology, on technical accounting and financial reporting matters. Prior to joining CFGI, Nate was a Manager in the Accounting Policy group at NorthStar Asset Management Group, Inc. Nate was responsible for the preparation of the SEC filings for NorthStar and also advised other controllers in the group companies for the implementation of accounting standards and preparation of SEC filings. Nate was also a Manager within the Financial Accounting Advisory Services group at Ernst & Young and was a Senior Auditor at Deloitte.
Prior to joining Cullinan, Kelley served as a Manager of Finance at Intarcia Therapeutics, where she was responsible for being a core contributor to monitoring the financial health and planning process of the company. Kelley graduated with a BS in Accounting from San Jose State University and boasts 10+ years of experience in Finance and Accounting.
Ray has served as our Chief Legal Officer since December 2020. Before joining the Company, Ray served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Intarcia Therapeutics, Inc. from September 2013 through April 2020. Prior to this, he served at Ariad Pharmaceuticals Inc., or Ariad, from 2008 through 2013 as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer. Prior to his tenure at Ariad, Ray served in increasing roles of responsibility at Bristol-Myers Squibb from 1988 until 2008, most recently as Chief Counsel, Global Marketing and Strategic Development. Ray has also served on various private company boards of directors. Ray holds a B.A. from Fordham University and a J.D. from Fordham University School of Law.
Prior to joining Cullinan, Mark led the drug substance development activities at Corvidia Therapeutics, an early stage virtual biotech, where he was responsible for managing the network of contract manufacturing, development, and testing laboratories for most all aspects of development and clinical manufacture of the lead product, ziltivekimab. On the strength of the overall ziltivekimab program, Corvidia was acquired by Novo Nordisk in July, 2020. Prior to Corvidia, Mark worked at Epirus Pharmaceuticals, Percivia, Pfizer, and Wyeth, all focused on biotherapeutic development.
Lori has more than 30 years of experience in providing administrative support to ensure efficient operation of the office. Prior to joining Cullinan Oncology Lori worked at UBS Financial, Barclays and Merrill Lynch.
Prior to joining Cullinan, Natalia served as a Clinical Trial Manager at Infinity Pharmaceuticals where she was the global operational lead for MARIO-275, their phase II trial in urothelial cancer. Previously, she was at Unum Therapeutics for three years where she helped bring their first-in-human ACTR platform technology to the clinic for both hematologic and solid tumor malignancies. She also led Unum’s long-term observational trial during her tenure. Natalia began her career on the CRO side of the industry at Harvard Clinical Research Institute working on trials in Phases I-III in a wide range of indications.
Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Cullinan Oncology, Jeff most recently served as CFO at Amylyx Pharmaceuticals where he established the company’s Finance and Accounting operations and oversaw the successful completion of a Series B financing. Jeff joined Amylyx after serving as a Vice President at BlueRock Therapeutics, an engineered cell and gene therapy company, where he played a leading role in building out the finance function and supporting its sale to Bayer AG in a transaction that valued BlueRock up to $1 billion. Previously, Jeff held corporate finance and strategy roles at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, and in Healthcare Investment Banking and Equity Capital Markets at RBC Capital Markets and Credit Suisse. 
Most recently, Kerry was Director of Discovery and Translational Biology, and led multiple oncology programs. She held prior positions at both Aveo and Wyeth, and her drug development background spans preclinical to Phase 2 assets and includes biologics, ADC’s, and small molecules.
Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics (NASDAQ:MGNX), where he led the company’s evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. This included the translation of ten new molecules into the clinic, including early phase and/or proof-of-concept studies with bispecific molecules, checkpoint inhibitors, Fc-optimized antibodies and antibody drug conjugates, as well as the design and execution of registration-directed studies.
Erica is an Executive Assistant and Office Supervisor at Cullinan Oncology.
